Filing Flows › AbCellera Biologics (ABCL) › Q2 2026
AbCellera Biologics (ABCL) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
AbCellera Biologics (ABCL) reported revenue of $4.0M for the second quarter 2026 (Q2 2026), -76% from a year earlier and -51% from the quarter before.
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.0M | -51% | -76% |
| Operating profit | −$62.8M | — | — |
| Net earnings | −$55.4M | — | — |
| Operating cash flow | $25.9M | — | — |
| Free cash flow | $23.8M | — | — |
What changed
Revenue was $4.0M in Q2 2026, down 76% year over year and down 51% from the previous quarter. Research fees was the largest line at 96% of revenue. Licensing and royalty revenue lost $10.3M year over year (down 99%), 79% of the total change.
Operating costs exceeded revenue by $62.8M, an operating margin of -1550.0%. Total costs grew 0% against a revenue fall of 76%. The fastest-growing cost line was Other operating costs (+28%). The quarter ended with a net loss of $55.4M, wider than the previous quarter's $43.2M loss.
Operating cash flow was $25.9M. Non-cash charges added back $7.0M of depreciation and amortization and $12.3M of share-based compensation. Working capital and other items added $62.1M. Capital expenditures of $2.1M left free cash flow of $23.8M.
Questions
What was AbCellera Biologics' revenue in the second quarter 2026?
AbCellera Biologics (ABCL) reported revenue of $4.0M for the second quarter 2026 (Q2 2026), -76% from a year earlier and -51% from the quarter before.